2020 ASCO Virtual Direct™ Highlights
Hematologic Oncology
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Update on AML: Are Ivosidenib and Enasidenib Good Options to Be Added to the Backbone of HMAs?
FEATURING
Ravi Vij
- 114 views
- July 22, 2020
- 1
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Update on Myeloma: KRd vs. VRd for Initial Therapy of Newly Diagnosed Disease, Weekly Selinexor Combo vs. Vd After Prior Therapy, Safety and Tolerability of Belantamab Mafodotin + Bortezomib/Dexamethasone in R/R Disease
FEATURING
Ravi Vij
- 344 views
- July 22, 2020
- 2